ETF Holdings Breakdown of IBRX

Stock NameImmunitybio Inc
TickerIBRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45256X1037
LEI529900J9XLBR4HFL4B83

IBRX institutional holdings

The following institutional investment holdings of IBRX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 77,405USD 185,772
2025-10-17 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 284,534USD 682,882
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 602,686USD 1,446,446
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 602,686USD 1,446,446
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 216,618USD 519,883 -7.5%
Total =1,783,929 USD 4,281,429
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with IBRX

HC Wainwright Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 208.88% from the company’s previous close. A number […] - 2025-09-12 03:00:44
D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $24.00 target price on the stock. IBRX has been the subject of a number of other research reports. HC Wainwright […] - 2025-09-10 02:40:51
Stock Traders Buy High Volume of Call Options on ImmunityBio (NASDAQ:IBRX)
ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 18,890 call options on the company. Thisisanincreaseof283% compared to the average volume of 4,932 call options. ImmunityBio Price Performance Shares of IBRX opened at $2.71 on Friday. ImmunityBio has a 1 year low of $1.83 […] - 2025-08-15 02:34:48
ImmunityBio, Inc. (NASDAQ:IBRX) Stake Raised by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 42.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,992 shares of the company’s stock after acquiring an additional 13,139 shares during the period. […] - 2025-08-11 05:32:50
Crestwood Advisors Group LLC Buys 6,000 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)
Crestwood Advisors Group LLC grew its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 37.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 22,200 shares of the company’s stock after purchasing an additional 6,000 shares during the quarter. Crestwood Advisors Group LLC’s holdings in ImmunityBio were worth $67,000 at […] - 2025-07-24 05:48:55
SBI Securities Co. Ltd. Sells 9,900 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)
SBI Securities Co. Ltd. cut its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 43.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,777 shares of the company’s stock after selling 9,900 shares during the period. SBI Securities Co. Ltd.’s […] - 2025-07-21 06:58:48
Xponance Inc. Buys New Stake in ImmunityBio, Inc. (NASDAQ:IBRX)
Xponance Inc. bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 11,021 shares of the company’s stock, valued at approximately $33,000. Several other large investors have also recently made changes to their positions in IBRX. Swiss National […] - 2025-07-21 05:38:57
Cambridge Investment Research Advisors Inc. Acquires Shares of 17,950 ImmunityBio, Inc. (NASDAQ:IBRX)
Cambridge Investment Research Advisors Inc. acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 17,950 shares of the company’s stock, valued at approximately $54,000. Several other institutional investors and hedge funds have also bought and sold shares of IBRX. Vanguard Group Inc. […] - 2025-07-16 04:30:59
Vontobel Holding Ltd. Has $48,000 Stake in ImmunityBio, Inc. (NASDAQ:IBRX)
Vontobel Holding Ltd. decreased its stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 33.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,000 shares of the company’s stock after selling 8,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in ImmunityBio […] - 2025-07-10 05:02:55
Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight
ImmunityBio (NASDAQ:IBRX – Get Free Report) was upgraded by investment analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a $5.00 price target on the stock, up from their previous price target of $4.25. Piper Sandler’s price objective […] - 2025-05-22 02:44:47
D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock. Separately, HC Wainwright reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, May […] - 2025-05-14 05:04:48
ImmunityBio (NASDAQ:IBRX) Given Buy Rating at HC Wainwright
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 218.73% from the stock’s current price. Separately, D. Boral Capital reissued […] - 2025-05-14 05:04:48
ImmunityBio, Inc. (NASDAQ:IBRX) Stake Reduced by Legal & General Group Plc
Legal & General Group Plc lessened its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 7.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 131,364 shares of the company’s stock after selling 11,161 shares during the quarter. Legal & General Group Plc’s holdings in ImmunityBio were worth $336,000 at […] - 2025-05-01 05:24:53
Geode Capital Management LLC Decreases Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)
Geode Capital Management LLC cut its stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 0.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,840,918 shares of the company’s stock after selling 5,757 shares during the period. Geode Capital Management LLC’s holdings […] - 2025-04-24 04:58:48
LPL Financial LLC Raises Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)
LPL Financial LLC grew its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 67.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,449 shares of the company’s stock after buying an additional 103,495 shares during the period. LPL […] - 2025-04-24 04:10:54
Teacher Retirement System of Texas Has $107,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)
Teacher Retirement System of Texas grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,742 shares of the company’s stock after acquiring an additional 7,067 shares during the period. […] - 2025-04-03 04:54:52
Comparing ImmunityBio (NASDAQ:IBRX) & Curis (NASDAQ:CRIS)
ImmunityBio (NASDAQ:IBRX – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations. Analyst Recommendations This is a summary of recent ratings and […] - 2025-04-02 02:20:51
Stephens Inc. AR Invests $26,000 in ImmunityBio, Inc. (NASDAQ:IBRX)
Stephens Inc. AR acquired a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,090 shares of the company’s stock, valued at approximately $26,000. Several other large […] - 2025-02-18 06:16:55
After Hours Most Active for Jan 27, 2025 : VTWO, NVDA, AAPL, T, QQQ, IBRX, GOOGL, BAC, AA, GAP, BABA, XOM
The NASDAQ 100 After Hours Indicator is up 67.15 to 21,194.43. The total After hours volume is currently 157,887,661 shares traded.The following are the most active stocks for the after hours session: Vanguard Russell 2000 ETF (VTWO) is +0.1 at $91.72, with 9,652,088 shares trad - 2025-01-27 19:24:58

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.